Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Ascending, Open Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of VG161 Combined With Nivolumab Injection in Subjects With Metastatic Gastric Cancer

NCT06008925 is registered in ClinicalTrials.gov with CNBG-Virogin Biotech (Shanghai) Ltd. as lead sponsor.

NCT NCT06008925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06008925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Ascending, Open Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of VG161 Combined With Nivolumab Injection in Subjects With Metastatic Gastric Cancer
Lead sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 17, 2022
Completion date
June 30, 2026
Enrollment
43 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastric cancer